An update on diagnostic tissue-based biomarkers in testicular tumors

Hum Pathol. 2023 Mar:133:32-55. doi: 10.1016/j.humpath.2022.07.020. Epub 2022 Aug 3.

Abstract

Testicular cancer is rare overall but comprises the most common solid malignancy diagnosed in young men aged ∼20-40 years. Most testicular neoplasms generally fall into 2 broad categories: germ cell tumors (GCTs; ∼95%) and sex cord-stromal tumors (SCSTs ∼5%). Given the relative rarity of these tumors, diagnostic biomarkers are highly relevant for their diagnosis. Over the past several decades, diagnostic biomarkers have improved dramatically through targeted immunohistochemical and molecular characterization. Despite these recent advances, most markers are not perfectly sensitive or entirely specific. Therefore, they need to be used in combination and interpreted in context. In this review, we summarize tissue-based biomarkers relevant to the pathologist, with a focus on practical diagnostic issues that relate to testicular GCT and SCST.

Keywords: Biomarkers; Germ cell tumors; Immunohistochemistry; Sex cord-stromal tumors; Testicular cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Female
  • Humans
  • Male
  • Neoplasms, Germ Cell and Embryonal* / diagnosis
  • Ovarian Neoplasms* / pathology
  • Sex Cord-Gonadal Stromal Tumors* / diagnosis
  • Sex Cord-Gonadal Stromal Tumors* / pathology
  • Testicular Neoplasms* / diagnosis
  • Testicular Neoplasms* / pathology

Substances

  • Biomarkers, Tumor